1. Home
  2. XBIT vs HNNA Comparison

XBIT vs HNNA Comparison

Compare XBIT & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.26

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Logo Hennessy Advisors Inc.

HNNA

Hennessy Advisors Inc.

HOLD

Current Price

$10.09

Market Cap

78.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
HNNA
Founded
2005
1989
Country
United States
United States
Employees
N/A
18
Industry
Pharmaceuticals and Biotechnology
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
78.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
XBIT
HNNA
Price
$2.26
$10.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.6K
4.2K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
5.57%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.77
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$8.90
52 Week High
$3.61
$13.19

Technical Indicators

Market Signals
Indicator
XBIT
HNNA
Relative Strength Index (RSI) 39.23 46.90
Support Level $2.27 $9.70
Resistance Level $2.42 $10.00
Average True Range (ATR) 0.05 0.16
MACD -0.00 -0.02
Stochastic Oscillator 10.80 21.03

Price Performance

Historical Comparison
XBIT
HNNA

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.

Share on Social Networks: